- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.06. | Biodesix, Inc.: Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs | 1 | GlobeNewswire (USA) | ||
| 04.06. | Biodesix auf der 45. jährlichen William Blair Growth Stock Konferenz: Fokus auf Lungengesundheit | 3 | Investing.com Deutsch | ||
| 30.05. | BIODESIX INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 22.05. | Biodesix, Inc.: Biodesix Announces New Data on the VeriStrat Test to be Presented at the 2025 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 21.05. | BIODESIX INC - 8-K, Current Report | 1 | SEC Filings | ||
| 21.05. | Scotiabank cuts Biodesix stock target to $2, maintains outlook | 3 | Investing.com | ||
| 15.05. | Biodesix, Inc.: Biodesix Announces New Clinical and Economic Data for its Nodify Lung Tests at ISPOR and ATS | 111 | GlobeNewswire (Europe) | LOUISVILLE, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced that new data will be presented at the International Society for... ► Artikel lesen | |
| 15.05. | Biodesix Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | 1 | Benzinga.com | ||
| BIODESIX Aktie jetzt für 0€ handeln | |||||
| 14.05. | Biodesix, Inc.: Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award | 1 | GlobeNewswire (USA) | ||
| 14.05. | Biodesix Analysts Lower Their Forecasts After Downbeat Q1 Results | 1 | Benzinga.com | ||
| 14.05. | Biodesix GAAP EPS of -$0.08 misses by $0.02, revenue of $18M misses by $3.23M | 3 | Seeking Alpha | ||
| 14.05. | Biodesix stock rating cut to Market Perform at William Blair | 5 | Investing.com | ||
| 14.05. | Canaccord cuts Biodesix stock target to $1.50, keeps buy rating | 1 | Investing.com | ||
| 14.05. | Biodesix revises 2025 revenue guidance to $80M-$85M amid sales force reconfiguration and primary care expansion | 1 | Seeking Alpha | ||
| 13.05. | BIODESIX INC - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.05. | Biodesix, Inc.: Biodesix Announces First Quarter 2025 Results and Highlights | 123 | GlobeNewswire (Europe) | Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to... ► Artikel lesen | |
| 29.04. | Biodesix, Inc.: Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025 | 1 | GlobeNewswire (USA) | ||
| 23.04. | Biodesix, Inc.: Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types | 3 | GlobeNewswire (USA) | ||
| 17.04. | BIODESIX INC - 8-K, Current Report | 1 | SEC Filings | ||
| 04.03. | Biodesix, Inc. (BDSX): Among Penny Stocks with Insider Buying in 2025 | 1 | Insider Monkey |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PAION | 0,011 | -27,03 % | Paion Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| GUARDANT HEALTH | 43,430 | 0,00 % | Exas, Guardant, Gilead among gainers as Supreme Court ensures free preventive care | ||
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
| BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen |
BIODESIX INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,252 Euro und damit -9,07 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODESIX INC finden Sie auf Wallstreet Online.